1. In Vivo
  2. >>Innovation

Microbot Medical Hopes To Bring First Disposable Endovascular Robot To US Market

 
• By Marion Webb

Microbot Medical CEO Harel Gadot said a recent regulatory filing marks an important milestone in his company' efforts to bring the world’s first fully disposable endovascular robot to market.  

Robotic
• Source: Shutterstock

Microbot Medical Inc. expects its Liberty system to be the first company to introduce a fully disposable endovascular robotic system in the US in 2023, but still has a long regulatory pathway ahead.

On 31 March, Microbot announced it filed its pre-submission package for the Liberty Robotic System with the US Food and Drug Administration and plans to meet with regulators to address

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By Ian Taylor

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

More from In Vivo